Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - comparison of pharmacology and clinical efficacy
Open Access
- 1 January 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Medical Research
- Vol. 15 (12), 507-513
- https://doi.org/10.1186/2047-783x-15-12-507
Abstract
The incidence of nosocomial pneumonia involving methicillin resistant Staphylococcus aureus strains (MRSA) is on the rise worldwide For years van corny cm has been used as the drug of choice in the treatment of MRSA infections and was recommended as such by clinical guidelines There is growing evidence that vancomycin despite low resistance rates is a suboptimal therapeutic option in critically ill patients particularly in patients with pneumonia Disadvantages of vancomycin are i) slow bactericide action ii) poor penetration into pulmonary tissue iii) the globally slowly increasing vancomycin MICs (creep) that re suit in increased clinical failure despite being susceptible according to defined break points and iv) nephrotoxicity in contrast to other novel antibiotics with MRSA activity Linezolid is currently approved for the treatment of nosocomial pneumonia in the USA and Europe Several studies have compared vancomycin with linezolid for nosocomial pneumonia with conflicting results This review compares both substances regarding pharmacodynamics resistance safety and clinical efficacy and discusses preliminary data of the ZEPHyR study This study compared linezolid versus vancomycin in patients with pros en MRSA pneumonia and was the largest trial ever conducted in this populationKeywords
This publication has 71 references indexed in Scilit:
- Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis*Critical Care Medicine, 2010
- Efficacy Profiles of Daptomycin for Treatment of Invasive and Noninvasive Pulmonary Infections with Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2010
- Early- and Late-Onset Pneumonia: Is This Still a Useful Classification?Antimicrobial Agents and Chemotherapy, 2009
- Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumoniaThe Lancet Infectious Diseases, 2009
- Hospitalizations and Deaths Caused by Methicillin-ResistantStaphylococcus aureus, United States, 1999–2005Emerging Infectious Diseases, 2007
- LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)Diagnostic Microbiology and Infectious Disease, 2007
- Impact of Empirical-Therapy Selection on Outcomes of Intravenous Drug Users with Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2007
- Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5-Year PeriodJournal of Clinical Microbiology, 2006
- Good Clinical Outcomes but High Rates of Adverse Reactions during Linezolid Therapy for Serious Infections: a Proposed Protocol for Monitoring Therapy in Complex PatientsAntimicrobial Agents and Chemotherapy, 2006
- Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone AntibacterialClinical Pharmacokinetics, 2003